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Abstract 20 
 The clinical outcome of Leishmania infantum infection in dogs varies from subclinical 21 
infection to severe disease.  Researchers attribute this variability in clinical manifestations to 22 
the ability of the immune response to limit pathogen multiplication and dissemination, which 23 
is, in part, likely determined by the immune response genes.  The aim of this study was to test 24 
the hypothesis that MHC class II genes are associated with disease outcome of experimental 25 
L. infantum infection in Beagles.  Dog leukocyte antigen (DLA) class II haplotypes were 26 
characterised by sequence-based typing of Beagle dogs experimentally infected with L. 27 
infantum during vaccine challenge studies.  Variability of response to infection was 28 
determined by clinical score, serology and quantification of L. infantum DNA in the bone 29 
marrow over the study period.   30 
 31 
 Dogs showed limited DLA diversity and the DLA profiles of dogs recruited for the 32 
different vaccine challenge studies differed. There were variable responses to infection, 33 
despite the apparent restriction in genetic diversity.  One haplotype DLA-DRB1*001:02--34 
DQA1*001:01--DQB1*002:01 was associated with increased anti-Leishmania antibodies in 35 
one infection model, but no DLA associations were found in other groups or with parasite 36 
load or clinical score.  Examination of this particular DLA haplotype in a larger number of 37 
dogs is required to confirm whether an association exists with the immune or clinical 38 
responses to L. infantum infection. 39 
 40 
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Introduction 42 
The protozoan parasite Leishmania infantum is most commonly transmitted between 43 
mammalian hosts via biting female sandflies, belonging to the genera Phlebotomus or 44 
Lutzomyia.  The distribution of such vectors largely limits infection to particular geographical 45 
regions (Killick-Kendrick, 1999).  Leishmania infantum is endemic in the Mediterranean 46 
basin, Central and South America and parts of Asia and Africa (Palatnik-de-Sousa and Day, 47 
2011).  Europe has approximately 2.5 million infected dogs, based on seroprevalence data, 48 
(Moreno and Alvar, 2002) although no official surveillance system for recording the number 49 
of dogs infected exists.  50 
 51 
Canine leishmaniosis presents with diverse clinicopathological abnormalities and 52 
clinical outcomes.  Furthermore, there appears to be significant individual variation following 53 
infection with the L. infantum parasite with only some dogs developing clinical disease 54 
(Baneth et al., 2008).  In an experimental infection model utilised in vaccine studies, high 55 
doses of amastigotes or promastigotes are given IV, but even under these circumstances, 56 
some dogs do not develop clinical signs over the study period, despite a relatively large 57 
challenge dose (Campino et al., 2000; Costa et al., 2013).   58 
 59 
The non-specific clinical signs and the absence of a reference standard test complicate 60 
the diagnosis of canine leishmaniosis (Rodriguez-Cortes et al., 2010).  Serological testing is 61 
often used for diagnostic purposes, to monitor the infection course and/or the response to 62 
treatment.  However, while Leishmania-specific antibody levels do not correlate with disease 63 
protection, high antibody reactivity is associated with clinical disease (Reis et al., 2006). 64 
Detection of Leishmania DNA in the tissues with PCR is a sensitive alternative technique for 65 
identifying infection (Cortes et al., 2004) and high parasite load in the tissues is associated 66 
with clinical disease (Dos-Santos et al., 2008). 67 
 68 
Previous canine studies appeared to confirm a role for T-cell mediated immunity 69 
(CMI) in resistance to canine leishmaniosis, with IFN-γ, produced by stimulated lymphocytes 70 
from subclinically infected dogs, able to lyse Leishmania infected macrophages, in contrast 71 
with lymphocytes from clinically infected dogs (Pinelli et al., 1995). Despite several studies 72 
examining cell mediated immunity in dogs, a clear picture of the T-helper phenotypes 73 
associated with disease outcome has not emerged and results are often contradictory (Hosein 74 
et al., 2017).  Therefore, CMI assays are infrequently performed to diagnose clinical 75 
leishmaniosis and their utility for predicting outcome of infection is not always reliable. 76 
 77 
The genetic background of the host might play a role in determining the outcome of 78 
infection with L. infantum and differences in susceptibility between different dog breeds has 79 
been suggested.  The Ibizan hound in particular has been identified as a potentially resistant 80 
breed (Solano-Gallego et al., 2000).  Other studies have suggested that the Cocker spaniel 81 
and Boxer breeds might be more at risk of developing clinical disease (Franca-Silva et al., 82 
2003).  As the outcome to L. infantum infection is largely dependent on the host immune 83 
response, much of the genetic research has focussed on immune response genes that might 84 
determine the outcome of infection. 85 
 86 
Dog leukocyte antigen (DLA) class II genes determine antigen presentation by MHC 87 
class II molecules and influence the subsequent immune response; therefore, they might also 88 
determine the ability to control L. infantum parasite numbers in tissues and clinical outcome. 89 
A previous study has examined DLA genes in a naturally infected group of cross breed dogs 90 
in Brazil and DLA-DRB1 015:02 was associated with increased risk of L. infantum infection 91 
(Quinnell et al., 2003).  The impact of the DLA background of laboratory Beagle dogs on the 92 
response to experimental infection, undertaken as part of vaccine efficacy studies, has not 93 
been examined and immunogenetic profiling of dogs enrolled in vaccine challenge studies 94 
might provide valuable additional information in terms of the response to vaccination and the 95 
clinical outcome following experimental infection.  In this study, DLA class II genes were 96 
examined in four groups of Beagle dogs experimentally challenged with L. infantum and 97 
studied post-challenge as part of vaccine studies. 98 
 99 
Materials and methods 100 
Study population  101 
EDTA blood samples were taken as part of ongoing commercial studies into candidate 102 
vaccines.  Blood sampling was undertaken by appropriately trained Zoetis staff in accordance 103 
with the relevant regulatory approval at the partner institution. Approval for use of residual 104 
EDTA blood samples in research was granted from the Royal Veterinary College Ethics and 105 
Welfare Committee (Approval number URN 2014 1292, 3rd September 2014). 106 
 107 
Blood samples were obtained from laboratory Beagle dogs (n=90) enrolled as 108 
unvaccinated controls in one of four vaccination/challenge studies undertaken in Spain. As 109 
part of these studies, dogs were challenged with L. infantum (MCRI/ES/2006/BCN-720 110 
MON 1) by IV injection of either amastigotes or promastigotes, according to the protocol 111 
shown in Supplementary Table 1.  Dogs in studies A (n=30) and B (n=17) were challenged 112 
with 1 x106 promastigotes, dogs in study C (n=23) were challenged with 5 x107 promastigotes 113 
and dogs in study D (n=20) were challenged with 2 x108 amastigotes. Dogs were monitored 114 
for a period of up to 2 years and were regularly examined and subjected to diagnostic testing 115 
during this period.  Dogs were allocated a clinical score (0-2/2), for clinical parameters which 116 
included body condition, demeanour, skin lesions, mucous membrane colour, ocular lesions, 117 
lymph node size (Supplementary Table 2).  A combined clinical score was then allocated for 118 
each time point, based on sum of the individual scores.  Dogs were monitored for between 5 119 
and 19 months and clinical scores were assigned every 2-8 weeks, depending on the study 120 
design.   121 
 122 
Diagnostic testing 123 
ELISA testing was performed to assess the presence of anti-Leishmania antibodies as 124 
previously described with some modifications (Solano-Gallego et al., 2014).  Briefly, 96-well 125 
flat-bottomed plates (Maxisorb, Nunc) were coated overnight at 4 °C with 100 µL per well of 126 
diluted sonicated crude L. infantum promastigotes (20 µg/ml; MCAN/ES/92/BCN-83/MON-127 
1), then plates were emptied and left to dry at room temperature.  Canine serum was diluted 128 
1:200 in phosphate buffered saline (PBS) supplemented with 0.05% Tween 20 (PBST; Sigma 129 
Aldrich) containing 10 g/L dried skimmed milk (PBSTM) and 100 µL per well was added in 130 
duplicate.  A calibrator sample was diluted 1:400 and then through 1:2 dilutions to 1: 12800 131 
to create a 6-point standard curve.  Plates were incubated for 60 min at 37 °C, then washed 132 
thoroughly with PBST.  Plates were incubated with 100 µL of sheep anti-dog IgG conjugated 133 
to horseradish peroxidase (Serotec) for 60 min at 37 °C.  Absorbance was measured at 492 134 
nm on an automatic ELISA reader (Thermoscientific MULTISKAN Spectrum).  The results 135 
were expressed in ELISA units (EU) in relation to a known positive serum (used for 136 
calibration) and arbitrarily set at 100 EU. The positive cut-off was determined for each new 137 
antigen batch from the mean + 3 standard deviations (SD) for 50 serum samples from non-138 
infected dogs collected before the study commenced. Serology was performed in three of the 139 
four studies, every 2-6 weeks, depending on study design. 140 
 141 
Quantitative PCR was performed on bone marrow samples as previously described 142 
(Francino et al., 2006). Quantitative analysis was performed through absolute quantification 143 
from a 6-point standard curve, with serial dilutions of a parasite culture, top standard 144 
equivalent to 500 promastigotes, and values were expressed as genome copy/mL bone 145 
marrow aspirate.  Testing for L. infantum DNA in bone marrow aspirates was performed in 146 
all dogs every 2-6 months.  147 
 148 
Statistical analysis 149 
Correlation between clinical score, ELISA and qPCR data was assessed using 150 
Kendall’s Tau correlation.  Bias corrected and accelerated bootstrapping was performed to 151 
provide more robust 95% confidence intervals for this non-normally distributed data set, 152 
(1000 bootstrap samples were used except where indicated).  Correlations were performed 153 
across all time points. 154 
 155 
Each study group was analysed separately, since challenge and dose was likely to 156 
influence outcome.  At each monthly time point studied and for each phenotype parameter 157 
(clinical score, serology and parasite load determined by qPCR), dogs were ranked based on 158 
whether they were positioned above or below the median score.  Dogs consistently (>70% of 159 
time points in study) above the median score for each phenotype were categorised as high.  160 
Dogs consistently (>70% of time points in the study) below the median score for the 161 
phenotype were categorised as low.  All other dogs were categorised as medium for each 162 
phenotype.  Dogs that were euthanased as a result of L. infantum infection during the study 163 
period were assigned to the high category regardless of phenotyping method. 164 
 165 
Haplotype frequencies were calculated and were compared between groups using 166 
Fisher’s exact test, with Bonferroni correction when all haplotypes were examined 167 
concurrently, in SPSS Statistics v22 (IBM, Hampshire, UK).  Haplotype frequencies between 168 
different groups were compared for each phenotyping method.  Each group was analysed 169 
separately and then all groups were analysed together. 170 
 171 
DLA genotyping 172 
Genomic DNA (gDNA) was extracted from EDTA blood samples using the 173 
GenEluteTM Blood Genomic DNA Kit (Sigma-Aldrich), according to the manufacturer’s 174 
instructions.  Polymerase chain reaction (PCR) was used to amplify DNA using DLA-175 
specific primers. (2 µL at 20 pmol/µL final concentration; Sigma-Aldrich) were used.  176 
Primers used were DRB1 FOR CCGTCCCCACCAGCACATTTC, DRB1 M13 REV 177 
TGTAAAACGACGGCCAGTGTCACACACCTCAGCACCA (adapted from (Wagner et al., 178 
1996b)); DQA1 M13 FOR TGTAAAACGACGGCCAGTCTCAGCTGACCATGTTGC, 179 
DQA1 REV GGACAGATTCAGTGAAGAGAG (adapted from (Wagner et al., 1996a)); 180 
DQB1 M13 FOR TGTAAAACGACGGCCAGTCTCACTGGCCCGGCCTGTCTC, DQB1 181 
REV CACCTCGCCGCTGAACGTG (adapted from (Wagner et al., 1998).  Each reaction 182 
contained 5 µL Hi-Spec additive, 2.5 µL ImmoBuffer, 1.25 µL MgCl2 (2.5mM final 183 
concentration), 0.25 µL deoxynucleotide triphosphates (1 mM final concentration of all 184 
dNTPs) and 0.1 µL (1.25 IU) Immolase DNA polymerase (Bioline). 185 
 186 
PCR was performed using a G-Storm GS1 Thermal Cycler (Gene Technologies). 187 
Reactions were heated to 95 °C for 10 min, followed by 35 cycles consisting of 94 °C for 40 188 
s, 55 °C for 30 s for DQA1 or 60 °C for DRB1 and DQB1, and 72 °C for 1 min, with a final 189 
extension step at 72 °C for 10 min. PCR products were processed using the GenElute PCR 190 
Clean-up Kit (Sigma-Aldrich) and submitted for sequencing (Source Bioscience) using M13F 191 
primer. 192 
 193 
Sequencing results were analysed using CLC Workbench v 6.9.1 (CLC bio).  DLA 194 
alleles were assigned using SBT Engine 3.6.1 software (GenDx).  Three locus haplotypes 195 
were assembled from the assigned alleles, based on previous data regarding common 196 
haplotypes in Beagle dogs (Soutter et al., 2015).   197 
 198 
Results 199 
Clinical scoring 200 
Examination of clinical score data revealed variability in clinical signs and disease 201 
severity between individual dogs that had received the same infection dose and type.  There 202 
was a variable clinical picture over time, with most dogs having higher clinical scores 203 
towards the end of the study period (a representative example of clinical scores for some 204 
individual dogs in study B is shown in Fig. 1).  In all groups, some individuals began to 205 
develop clinical signs relatively quickly; with enlargement of peripheral lymph nodes 2-6 206 
weeks post-infection.  Skin lesions appeared from 2 months post-infection and evidence of 207 
multi-systemic disease and higher clinical scores from 7 months onwards in some 208 
individuals.  Two groups (C and D) were monitored for 6 and 5 months post-infection, 209 
respectively, and more severe or multi-systemic clinical signs were not observed in these 210 
groups.  211 
 212 
Serology 213 
All dogs were seropositive for Leishmania-specific antibodies by the end of their 214 
respective study periods in the three studies that included serological testing.  Leishmania-215 
specific antibodies increased over time after infection in all studies.  Leishmania antibody 216 
reactivity varied between dogs receiving the same challenge and dose at the same time post-217 
infection (a representative example of serology results for some individual dogs [study B] is 218 
shown in Fig. 2). 219 
 220 
Parasite load  221 
Almost all dogs were qPCR positive for Leishmania DNA in bone marrow by the end 222 
of their respective study periods.  Most dogs that had received IV amastigote challenge were 223 
qPCR positive in the bone marrow at the first time point where this was assessed (2 months 224 
after infection).  When quantified, Leishmania DNA concentration in the bone marrow was 225 
highly variable between individuals, even within the same study at the same time point (a 226 
representative example of test results for some individual dogs [study B] is shown in Fig. 3).  227 
While Leishmania DNA in the bone marrow tended to increase over time for each group as a 228 
whole, some dogs within the group did not demonstrate a change in parasite load in the bone 229 
marrow over the study period. 230 
 231 
Categorisation of dogs based on outcome of infection 232 
Clinical scores, serology test results and parasite load estimation by qPCR failed to 233 
show any consistent relationships, despite expectations of a positive association (i.e. sick 234 
dogs showing high clinical scores, strong seropositivity and high parasite loads and the 235 
opposite for resistant dogs).  In Studies B and C, parasite DNA concentration in the bone 236 
marrow significantly correlated with Leishmania-specific antibodies (P<0.05), although no 237 
such correlation was demonstrated in study D (Supplementary Fig. 1). Clinical score did not 238 
correlate with Leishmania-specific antibodies nor qPCR test results in any of the study 239 
groups, except for Study B, where clinical score correlated inversely with Leishmania DNA 240 
concentration in the bone marrow (τ= -.252, BCa CI [-.396,-.061], P=0.013; Supplementary 241 
Figs. 2 and 3).  Therefore, we could not categorise dogs into susceptible vs. resistant 242 
phenotypes based on combining the available data for each individual dog.  Because the 243 
study population consisted of four different challenge trials, each with a different protocol, it 244 
was not considered appropriate to combine the dogs into a single cohort.  Therefore, it was 245 
decided to undertake further analysis separately for each study group and to phenotype the 246 
dogs independently, according to clinical score, serology or parasite load (Table 1). 247 
 248 
DLA typing 249 
We identified 10 different DLA haplotypes (found in two or more dogs) in this study, 250 
plus three other haplotypes found in single dogs only, with substantial variation in the DLA 251 
profile between study groups (Table 2). Two haplotypes were common between all four study 252 
groups, while four haplotypes were only present in one of the four groups.  The most 253 
common haplotype was DLA-DRB1*006:01--DQA1*005:01:1--DQB1*007:01.  Two DQB1 254 
alleles were amplified as part of the DLA-DRB1*019:01--DQA1*004:01--255 
DQB1*013:03/017:01 haplotype.  We could not ascertain whether both of these DQB1 256 
alleles are expressed as mRNA was not available.  A total of 10 homozygous dogs were 257 
observed, with between 2-3 homozygous dogs in each group. 258 
 259 
DLA association with clinical score 260 
The DLA allele or haplotype frequencies did not differ between groups based on 261 
clinical score in any of the individual studies (Supplementary Data Table 3), or when all four 262 
study groups were combined (χ2=22.91, df=26, P=0.64). 263 
 264 
DLA association with Leishmania serology 265 
When we compared DLA haplotype frequencies between categories based on 266 
serology test results, DLA haplotype frequencies differed between groups only in Study C 267 
(Table 3). Specifically, the DLA-DRB1*001:02--DQA1*001:01--DQB1*002:01 haplotype 268 
was more common in the high seropositivity group than the low seropositivity group 269 
(P=0.03, OR=15.4, 95%CI=1.5-170.0) or the medium seropositivity group (P=0.025, 270 
OR=6.3, 95%CI=1.3-30.5), but frequency of this haplotype did not differ between medium 271 
and low seropositivity groups (P>0.05).  The DLA-DRB1*006:01--DQA1*005:01:1--272 
DQB1*007:01 haplotype was more common in the medium seropositivity group than the 273 
high seropositivity group (P=0.013). Haplotype frequencies did not differ between groups in 274 
studies B or D (P>0.05; Supplementary Table 4).  Similarly, haplotype frequency between 275 
groups did not differ when all groups were combined (χ2=19.03, df=22, P=0.65). 276 
There was no association with DLA-DRB1 or DLA-DQA1 and seropositivity in any of the 277 
groups studied.  However, DLA-DQB1 allele 002:01 in study C was more common in the 278 
high seropositivity group than the medium seropositivity group (P=0.01, odds ratio [OR] 279 
=8.0, 95% confidence intervals [CI]=1.6-40.0) or the low seropositivity group (P=0.01, 280 
OR=15.0, 95% CI=2.02-111.2).  Conversely DLA-DQB1 allele 007:01 in study C was more 281 
common in the medium group than the high group (P=0.01, OR=∞). 282 
 283 
DLA association with Leishmania DNA concentration in the bone marrow  284 
When we compared DLA haplotype frequencies between categories based on parasite 285 
DNA concentration in the bone marrow, the DLA-DRB1*006:01--DQA1*005:01:1--286 
DQB1*007:01 haplotype was more common in the medium group than the low group 287 
(P=0.02, OR=22.0, 95% CI= 1.5-314.3) only in study B (Table 4), but no other differences 288 
existed (Supplementary Table 5).  Haplotype frequency between groups did not differ when 289 
all studies were combined (χ2=30.16, df =26, P=0.26). 290 
 291 
There was no association with DLA-DRB1 or DLA-DQB1 and parasite load in any of 292 
the groups studied.  However, DLA-DQA1 allele 001:01 was more common in the medium 293 
group than the low group in Study C (P=0.01, OR=10.0, 95%CI=1.76-56.9). 294 
 295 
Discussion 296 
We examined the relationship between variability in disease expression following 297 
experimental infection with L. infantum in unvaccinated Beagles used in vaccine studies and 298 
DLA haplotypes frequencies, to determine whether these immune response genes impacted 299 
the clinical outcome of infection.  Clinical scores and the clinical infection course were 300 
highly variable between dogs, as were serological responses and parasite detection in the 301 
bone marrow, although all dogs seroconverted and most dogs became qPCR positive.  As 302 
clinical score did not consistently correlate with the serological response or parasite load, 303 
each parameter was used separately to categorise dogs according to disease expression. We 304 
found a potential association between DLA haplotype and serological response to 305 
experimental infection with L. infantum in Beagles, although this was not found in all groups.  306 
There was no association between DLA haplotype and clinical disease expression after 307 
infection. 308 
 309 
All dogs in the study were experimentally infected with L. infantum by IV injection, 310 
which is not necessarily comparable with natural infection by biting sandflies.  Additionally, 311 
the infective dose of either promastigotes or amastigotes (1×106 parasites and 2×108 312 
parasites, respectively) was much greater than in natural infection, which researchers believe 313 
to be approximately 100-1000 parasites per bite (Saridomichelakis, 2009; Rogers, 2012).  In 314 
IV infection models, researchers believe that parasite dissemination to the organs and 315 
therefore clinical signs occur more quickly (Moreno and Alvar, 2002), which means that 316 
studies are less time consuming, although not truly representative of natural infection.  317 
However, since the dogs are kept in a controlled environment and are exposed to a fixed dose 318 
of parasite at a known time point, there are less random effects that could influence the 319 
outcome of infection, which is crucial in providing efficacy data for vaccine licencing and 320 
potentially useful in evaluating potential genetic factors associated with disease. 321 
 322 
Clinical scores were used to evaluate the nature and severity of clinical signs at 323 
different time points following IV infection with L. infantum.  Most dogs developed some 324 
degree of illness during the study and some dogs started to develop clinical signs at 2-3 325 
months post-infection, although more severe clinical signs were not evident until around 7 326 
months post-infection.  Our findings mirror those reported in other studies using IV infection 327 
methods, where clinical signs often appear from around 2-4 months post-infection (Carrera et 328 
al., 1996; Poot et al., 2005) and clinical outcomes of infection vary between dogs (Nieto et 329 
al., 1999; Campino et al., 2000). 330 
 331 
We used clinical scores to quantify the clinical signs observed in dogs over time and 332 
to distinguish very sick dogs from those with mild clinical signs.  However, dogs with 333 
moderate clinical scores were more difficult to evaluate, particularly in the absence of 334 
clinicopathological data.  Such data could have enabled us to use a clinical staging system 335 
such as the Leishvet guidelines or those proposed by the Canine Leishmaniasis Working 336 
Group (Solano-Gallego et al., 2009; Roura et al., 2013), which stage dogs based on clinical 337 
signs, clinicopathological abnormalities and Leishmania diagnostic testing information.  338 
However, clinical staging might not distinguish dogs predisposed to developing clinical 339 
disease from those that are more resistant to infection, when dogs are exposed to a high dose 340 
of pathogen in experimental infection and thus might not have been useful in phenotyping 341 
dogs. 342 
 343 
High Leishmania antibody reactivity accompanied by clinical and clinicopathological 344 
abnormalities is considered diagnostic for canine leishmaniosis (Solano-Gallego et al., 2011).  345 
Leishmania-specific antibody levels tended to increase over time regardless of the challenge 346 
type.  Previous studies have demonstrated that seroconversion following infection is variable 347 
with regards to the number of dogs that seroconvert and the time of seroconversion post-348 
infection with promastigote challenge (Nieto et al., 1999; Campino et al., 2000; Paranhos-349 
Silva et al., 2003). Assessment of cell mediated immunity was not performed as the 350 
relationship between T-helper phenotypes and disease outcome is still unclear (Maia and 351 
Campino, 2012) and thus could have further confounded efforts to categorise dogs based on 352 
outcome of infection.   353 
 354 
Quantitative PCR for detection of Leishmania DNA was used to confirm the presence 355 
of active infection and bone marrow aspirates have greater sensitivity for detection of parasite 356 
DNA by qPCR compared with peripheral blood samples (Francino et al., 2006; Hernandez et 357 
al., 2015). Most dogs in our study were qPCR positive in the bone marrow by the end of the 358 
study, similar to previously published studies (Leandro et al., 2001; Fernandez-Cotrina et al., 359 
2013). 360 
 361 
Dogs in our study displayed variability for all measured parameters, even those dogs 362 
that had received the same type of challenge, dose and were assessed at the same time after 363 
infection.  This might reflect differences in individual dogs’ immune responses to L. infantum 364 
and the ability to control parasite numbers and prevent disease.  In this study, the clinical 365 
score did not appear to correlate with serology test results or with parasite DNA detection in 366 
the bone marrow and, unexpectedly and counter-intuitively, in one study the clinical score 367 
was inversely correlated with parasite load in the bone marrow.  We did not anticipate this 368 
result, as several studies have indicated that dogs with demonstrable clinical signs following 369 
natural infection had elevated parasite loads in various tissues, as well as high antibody 370 
reactivity (Reis et al., 2006; Dos-Santos et al., 2008; Solano-Gallego et al., 2016).  Similarly, 371 
Leishmania-specific antibody positivity have been shown to correlate with parasite loads in 372 
the tissues of dogs naturally infected with L. infantum (Reis et al., 2006; Manna et al., 2009; 373 
Solano-Gallego et al., 2016).  It is possible that the experimental model using Beagle dogs 374 
resulted in a more homogenous clinical picture than one might expect with natural infection 375 
in a more outbred population.  Furthermore, it is possible that some dogs would have 376 
developed more severe clinical signs or multi-systemic clinical signs if they had been 377 
followed for a longer period of time.  It is also possible that clinical score does not adequately 378 
separate dogs that are somewhere in the middle of the disease spectrum and that this could be 379 
having an impact on lack of correlation between parameters.   380 
 381 
The individual study designs were somewhat variable, which meant that phenotyping 382 
dogs for a genetic association study was challenging and groups could not be easily 383 
combined. Additionally, as clinical disease was not consistently associated with anti-384 
Leishmania antibodies or with parasite load in the bone marrow, we could not categorise 385 
dogs, based on both clinical disease, immunological parameters and infection status, so we 386 
analysed the relationships of these parameters independently.  Alternative phenotyping 387 
methods could have assessed Leishmania-specific antibodies or Leishmania DNA 388 
concentration as a quantitative trait, or used all diagnostic parameters in a mixed model.  389 
However, as the samples and diagnostic data were obtained from several different studies, 390 
there was variability in the time points when these parameters were measured, which would 391 
have been difficult to model.  The phenotyping method used, while far from perfect, aimed to 392 
assess disease expression of each dog compared against the median disease expression of the 393 
group at each time point.  This method could then be used to distinguish individual dogs with 394 
disease expression consistently higher or lower than the group median and could therefore be 395 
considered to be highly susceptible or less susceptible for each parameter measured. All 396 
genetic association studies were likely to be underpowered as a result of the small sample 397 
size in each group and should be repeated in a larger cohort. 398 
 399 
Ten DLA haplotypes were identified in at least three Beagles. While this degree of 400 
restriction at the DLA locus is not as marked compared with some breeds, such as the 401 
Dobermann and the Rottweiler (Kennedy et al., 2002), it could affect the repertoire of peptide 402 
epitopes that can be presented to CD4+ T lymphocytes upon antigenic stimulation.  This 403 
limited diversity could also influence the response to experimental infection with L. infantum 404 
and vaccine responses such that a product deemed safe and efficacious in Beagles would not 405 
necessarily perform similarly in other dog breeds.  Furthermore, there was substantial 406 
variation in DLA profile between the different study groups, which indicates that 407 
immunogenetic profile has not been a factor in selection of dogs for these vaccine studies.  408 
However, differences in DLA profile between studies and within a study could result in 409 
variability in response to infection and vaccination between groups that is undesirable when 410 
trying to determine the efficacy of a new vaccine.  411 
  412 
None of the study groups differed in DLA haplotype frequencies when assessed 413 
against clinical outcomes.  One group showed a difference in haplotype frequencies between 414 
different serological responses.  Specifically, the DLA-DRB1*001:02--DQA1*001:01--415 
DQB1*002:01 haplotype was associated with a sustained elevation of anti-Leishmania 416 
antibodies over the study period, compared with dogs that had low or fluctuating antibody 417 
reactivity over the same period.  A previous study examining DLA haplotypes in crossbreed 418 
dogs in a Leishmania endemic region naturally infected with Leishmania reported that the 419 
DRB1 genotype 015:02 was associated with increased anti-Leishmania antibody levels and 420 
PCR positivity in the bone marrow, but did not demonstrate an association with clinical score 421 
(Quinnell et al., 2003).  This particular DRB1 allele was not present in the Beagle population 422 
and therefore could not be assessed.  Similarly, the DRB1*001:02 allele found to differ 423 
between groups in our study was not one of the common alleles described in a study of 424 
natural infection of Brazilian dogs.  Interestingly, the haplotype DLA-DRB1*015:01--425 
DQA1*009:01--DQB1*001:01, was found in dogs with high sustained parasite load in the 426 
bone marrow, but did not differ in frequency from those showing low parasite loads 427 
(P=0.06).  It is worth noting that DLA-DRB1*015:01 differs by a single amino acid from 428 
015:02 as a result of a single base pair substitution (Kennedy et al., 1998). 429 
 430 
Both our study and a previously published study examining naturally infected dogs 431 
(Quinnell et al., 2003) found a DLA association with the antibody response, but not with 432 
clinical disease expression.  DLA genes might influence antigen presentation and impact on 433 
the subsequent antibody response to L. infantum, but it is possible that there are other host 434 
and environmental factors that determine disease expression.  It is also possible that the 435 
clinical scoring system used is not a sufficiently robust method for distinguishing highly sick 436 
individual dogs from those with less severe clinical signs. 437 
 438 
In one group, dogs of another haplotype (DLA-DRB1*006:01--DQA1*005:01:1--439 
DQB1*007:01) that demonstrated intermediate anti-Leishmania seropositivity occurred more 440 
frequently than in those with high seropositivity.  However, in another group, the DLA-441 
DRB1*006:01--DQA1*005:01:1--DQB1*007:01 haplotype occurred more frequently in dogs 442 
with an intermediate parasite DNA concentration than in those showing low parasite DNA 443 
concentration in the bone marrow over the study period.  It is possible that the effect of 444 
homozygosity for DLA-DRB1*006:01--DQA1*005:01:1--DQB1*007:01 could be creating a 445 
spurious result for this particular haplotype.  Therefore, we repeated this analysis using 446 
number of dogs rather than number of haplotypes (data not shown) and there was not a 447 
significant association with seropositivity, or with parasite load (P >0.05; Supplementary 448 
Tables 6 and 7).   449 
 450 
Further work is required in a larger group of dogs receiving a similar experimental 451 
challenge of L. infantum or in a naturally infected cohort to identify if a true association 452 
between DLA genes and outcome of infection with L. infantum exists in dogs.  Examination 453 
of other immune response genes is also warranted and would expand existing knowledge on 454 
disease pathogenesis following infection and potentially identify new vaccine targets.  The 455 
selection of dogs for vaccine studies based on their genetic susceptibility profile might result 456 
in less individual variability and more robust trials.  Furthermore, early identification of dogs 457 
more predisposed to developing clinical disease would facilitate targeted prevention and 458 
vaccination strategies in endemic regions.  459 
 460 
Conclusions 461 
Beagle dogs demonstrated variability in their clinical and serological response to 462 
experimental infection with L. infantum and in their ability to control parasite load in the 463 
tissues, despite some degree of restriction in DLA diversity.  No DLA association with 464 
clinical score was observed. Investigation of the effect of DLA haplotypes on the outcome of 465 
experimental infection revealed a potential haplotype (DRB1*001:02--DQA1*001:01--466 
DQB1*002:01) which was associated with strong serological responses, which are normally 467 
counterproductive in this type of intracellular infection, although such an association could 468 
not be demonstrated in all groups.  Immunogenetic investigation of larger cohorts of dogs, 469 
following a standardised experimental challenge is warranted. Immunogenetic analysis could 470 
inform vaccine study design and appropriate selection of dogs for such trials, so that vaccine 471 
efficacy studies can be more economical and ethical, with a reduction in the number of dogs 472 
used. 473 
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  606 
Table 1.   607 
Number of dogs categorised by their disease phenotype according to phenotyping method 608 
 609 
Phenotyping 
method 
Disease  
phenotype 
Number of dogs (% of group) 
Study A 
(n=30) 
Study B 
(n=17) 
Study C 
(n=23) 
Study D 
(n=20) 
Clinical 
score 
High 17 (57%) 6 (35%) 8 (35%) 6 (30%) 
Medium 8 (27%) 7 (41%) 11 (48%) 10 (50%) 
Low 5 (16%) 4 (24%) 4 (17%) 4 (20%) 
Serology High a 5 (29.5%) 6 (26%) 2 (10%) 
Medium a 7 (41%) 11 (48%) 13 (65%) 
Low a 5 (29.5%) 6 (26%) 5 (25%) 
Parasite 
load(BM) 
High 19 (63%) 8 (47%) 5 (22%) 5 (25%) 
Medium 9 (30%) 3 (18%) 12 (52%) 11 (55%)  
Low 2 (7%) 6 (35%) 6 (26%) 4 (20%) 
a Serology not performed in this study 610 
  611 
Table 2.   612 
DLA haplotypes identified in Beagles experimentally infected with L. infantum. 613 
 614 
Haplotype Experimental infection study 
(number of haplotypes) 
DRB1 DQA1 DQB1 Study A Study B Study C Study D 
001:01 001:01 002:01 19a 2 5 3 
001:02 001:01 002:01 6 0 12 a 8 
002:01 009:01 001:01 1 2 0 1 
006:01 001:01 008:02 0 9 a 5 6 
006:01 001:01 008:01:1 0 2 0 0 
006:01 005:01:1 007:01 15 10 12 a 17 b 
008:01 003:01 004:01 0 6 a 3 1 
014:01 001:01 008:01:1 0 2 2 0 
015:01 009:01 001:01 17 a 0 2 2 
019:01 004:01 013:03 
/017:01 
0 0 5 1 
Other single haplotypes 2 1 0 1 
Total (haplotypes) 60 34 46 40 
Total number of dogs 30 17 23 20 
Total number of homozygous 
dogs 
2 3 2 3 
a One homozygous dog with this haplotype 615 
b Three homozygous dogs with this haplotype  616 
Table 3.  617 
DLA haplotypes in Study C phenotyped according to serology test results a 618 
Haplotype Number of haplotypes 
 
DRB1 DQA1 DQB1 
 
P 
High Medium Low 
001:01 001:01 002:01 2 2 1 0.7 
001:02 001:01 002:01 7b 4 1 0.01 
006:01 001:01 008:02 1 1 3 0.18 
006:01 005:01:1 007:01 0 9b 3 0.03 
008:01 003:01 004:01 0 1 2 0.23 
014:01 001:01 008:01:1 0 2 0 0.49 
015:01 009:01 001:01 0 1 1 0.99 
019:01 004:01 013:03/0
17:01 
2 2 1 0.7 
 
Total (haplotypes) 12 22 12   
Total (dogs) 6 11 6  
a Dogs with Leishmania-specific IgG (ELISA Units) above the median in 70% of the study 619 
time points are categorised as high susceptibility, Dogs with Leishmania-specific IgG levels 620 
below the median in 70% of the study time points are categorised as low susceptibility.  Each 621 
haplotype is made up of three loci- DLA-DRB1, DLA-DQA1 and DLA-DQB1.  P values 622 
comparing all three groups were determined by the Fisher’s exact probability test. 623 
b One dog homozygous for this haplotype 624 
c P<0.05  625 
Table 4.   626 
DLA haplotypes in Study B phenotyped according to Leishmania DNA concentration in the 627 
bone marrow a 628 
 629 
Haplotype Number of haplotypes 
P  
DRB1 DQA1 DQB1 
 
High Medium Low 
001:01 001:01 002:01 1 0 1 0.99 
002:01 009:01 001:01 1 0 1 0.99 
006:01 001:01 008:02 3 1 5b 0.45 
006:01 001:01 008:011 0 1 1 0.27 
006:01 005:01:1 007:01 5 4b 1 0.03c 
008:01 003:01 004:01 4b 0 2 0.52 
014:01 001:01 008:01:1 1 0 1 0.99 
Other single haplotypes 1 0 0 N/A 
Total (haplotypes) 16 6 12 
 
Total (dogs) 8 3 6 
 
N/A, Not applicable 630 
a Dogs with Leishmania DNA concentration (genome copy/mL) in the bone marrow above 631 
the median in 70% of the study time points are categorised as high susceptibility. Dogs with 632 
Leishmania DNA concentration in the bone marrow below the median in 70% of the study 633 
time points are categorised as low susceptibility.  Each haplotype is made up of three loci- 634 
DLA-DRB1, DLA_DQA1 and DLA-DQB1.  P values comparing all three groups were 635 
determined by the Fisher’s exact probability test. 636 
b One dog homozygous for this haplotype 637 
c P<0.05 638 
  639 
Figure legends 640 
 641 
Fig. 1. Clinical score over time for representative dogs in study B. Dogs in the high category 642 
had scores above the median in >70% of the time points. Dogs in the low category had scores 643 
below the median in >70% of the time points. 644 
 645 
  646 
Fig. 2. Serology results for representative dogs in study B. Leishmania-specific IgG was 647 
measured by ELISA. Dogs in the high category had scores above the median in >70% of the 648 
time points. Dogs in the low category had scores below the median in >70% of the time 649 
points. 650 
 651 
  652 
Fig. 3. Parasite load in the bone marrow for representative dogs in study B. Leishmania DNA 653 
in the bone marrow was measured by qPCR.  The median score for each time point is 654 
represented by a horizontal line. Dogs in the high category had scores above the median in 655 
>70% of the time points. Dogs in the low category had scores below the median in >70% of 656 
the time points. 657 
 658 
